Insmed announced breakthrough results from landmark respiratory study
Shares of Arctic Aurora LifeScience and Arctic Aurora Biotech Select holding Insmed appreciated 118% on positive Phase 3 results in bronchiectasis
Respiratory specialist Insmed provided a relief to both patients and investors as they announced positive results from their Phase 3 ASPEN trial, one of the most anticipated readouts in the biotech sector. The study tested Insmed’s brensocatib in a respiratory disease called bronchiectasis, a chronic lung condition with frequent exacerbations, infections and inflammation accompanied by excruciating cough, excess sputum production and shortness of breath. According to Insmed, this devastating disease affects more than 1 million patients globally who are currently without an approved treatment option. These promising results provide a huge advancement for the patient community.
In the ASPEN study, brensocatib reduced the rate of exacerbations by 21%, while it also increased the chance of being free of exacerbations by 41% among other benefits for patients. The drug’s side effect profile was also favorable, with the treatment arms experiencing numerically fewer adverse events than the placebo group. Based on these data, Insmed plans to file for regulatory approval by the end of the year.
Insmed’s stock price increased by 118% on the data, adding almost USD 4 billion to the company’s market cap. At the same time, the company also announced a USD 500 million equity offering.
Latest news
Arctic Asset Management - Vera Therapeutics soars on strong Phase 3 results in rare kidney disease
Arctic Aurora LifeScience and Arctic Aurora Biotech Select holding Vera Therapeutics increased more than 65% on June 2, upon announcing competitive phase 3 clinical data in IgAN, a severe kidney disorder.
Arctic Asset Management - Markedskommentar mai 2025
Mai måned viste en sterk utvikling i globale finansmarkeder, preget av økt risikovilje etter turbulensen i april. Verdensindeksen (MSCI World i NOK) steg 5,9 %, mens amerikanske aksjer, representert ved S&P 500 (USD), økte med 6,2 %. Oslo Børs (OSEFX, NOK) hadde også en positiv måned med en oppgang på 5,3 %, drevet av bred sektoroppgang hvor spesielt energi og finans bidro sterkt, mens sektoren defensivt konsum trakk ned, hovedsakelig på grunn av svak utvikling innen lakseoppdrett. Norden (VINX Index, NOK) steg markedet med 2,6 %, hvor industri og finans var de største positive bidragsyterne, mens eiendom bidro negativt.
Arctic Asset Management - The take outs in biotech continues
Sanofi acquires Arctic Aurora LifeScience portfolio company Blueprint Medicines.
On 2 June 2025, the French pharmaceutical company announced its agreement to acquire the Boston-based biotech company Blueprint Medicines in a deal valued at 9.5 billion USD. The acquisition centres on Blueprint's flagship drug, Ayvakit (avapritinib), which is the only approved treatment for advanced systemic mastocytosis in both the EU and the US.
Arctic Asset Management - Gjeld, usikkerhet og en fisk med potensial
I mai-episoden av Arctic Midt i Måneden ser vi nærmere på USAs økende gjeld og spør om landet har økonomisk styrke til å håndtere renteutgiftene. Vi snakker også om hvorfor "usikkerhet" er blitt et nøkkelord i årets rapporteringssesong, hvordan fondene er posisjonert – og hva som gjør en fisk til et fristende investeringscase. Forvalterne Trond Tømmerås og Alexander Larstedt Lager er gjester i studio hos investeringsdirektør Albert Collett.
Arctic Asset Management - What has caused the recent volatility in the healthcare sector?
Arctic Aurora LifeScience's CIO, Ulrica Slåne Bjerke, and portfolio manager, Daniel Bolanowski, share their thoughts on what caused the sector's bumpy ride in April and the first few days of May.
Arctic Asset Management - Markedskommentar april 2025
Nyhetsbildet i april var preget av sterke utspill fra president Trump der hans ‘Liberation Day’ tariff-annonseringer 2. april skapte ekstreme svingninger i finansmarkedene de påfølgende dagene.